AI-Reviewed Research, Clinical Excellence & Evidence-Based Practice— Curated and reviewed by practising aesthetic clinicians

    Aesthetic Intelligence · Industry News

    Industry News for Aesthetic Medicine

    Regulatory updates, product alerts, peer-reviewed research highlights, and HSI announcements — filtered by region. Editorial commentary, not promotional.

    6 items
    HSI🇬🇧 UK16 Jun 2026

    Aesthetic Intelligence — Volume 1, Issue 6 now online

    Issue 6 leads with a critical evidence review of the therapeutic peptide landscape, alongside articles on necrosis management, dermal filler complications, and migraine prevention with botulinum toxin.

    Source: HSI Editorial Board
    HSI🇬🇧 UK12 Jun 2026

    Aesthetic Intelligence assigned ISSN 2979-8116

    The Harley Street Institute’s open-access journal Aesthetic Intelligence has been formally registered with ISSN 2979-8116, supporting long-term indexing, citation, and archival permanence.

    Source: HSI Editorial Board
    Regulatory🇬🇧 UK10 Jun 2026

    MHRA reiterates position on unlicensed therapeutic peptides

    The Medicines and Healthcare products Regulatory Agency has reissued guidance clarifying that BPC-157, TB-500, and similar research peptides remain unlicensed for human use in the UK, with medicinal claims constituting an offence under the Human Medicines Regulations 2012.

    Regulatory🇬🇧 UK28 May 2026

    JCCP welcomes Department of Health licensing scheme progress

    The Joint Council for Cosmetic Practitioners reports that secondary legislation under Section 180 of the Health and Care Act 2022 is progressing, moving toward statutory licensing for non-surgical cosmetic procedures in England.

    Source: JCCP
    Regulatory🇬🇧 UK12 May 2026

    GMC updates CPD expectations for doctors practising aesthetic medicine

    The General Medical Council has issued supplementary guidance reinforcing that doctors practising in cosmetic interventions are expected to evidence CPD relevant to their scope of practice — a domain in which structured AiCE-aligned activity contributes.

    Source: GMC
    Regulatory🇬🇧 UK15 Jan 2026

    MHRA approves stronger dosage of semaglutide for weight management

    The Medicines and Healthcare products Regulatory Agency has approved a new maximum weekly dose of semaglutide up to 7.2mg for adults with obesity (BMI ≥30 kg/m²). The higher dose is administered as three consecutive 2.4mg injections following a structured escalation schedule, and does not apply to cardiovascular-risk indications.

    Source: MHRA

    Industry news is curated by the HSI editorial board. Items summarise external regulatory, product, and peer-reviewed developments and link to primary sources. They do not constitute clinical guidance. For peer-reviewed analysis, see the main journal.